a hearing must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 15, 1996.

A. Federal Reserve Bank of Boston (Robert M. Brady, Vice President) 600 Atlantic Avenue, Boston, Massachusetts 02106:

1. Bank of Boston Corp., Boston, Massachusetts; to acquire 100 percent of the voting shares of, and merge with The Boston Bancorp, Boston, Massachusetts, and thereby indirectly acquire South Boston Savings Bank, Boston, Massachusetts.

B. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. International Bancorporation, Golden Valley, Minnesota; to acquire 100 percent of the voting shares of Northern National Bank, Nisswa, Minnesota, a *de novo* bank.

2. White Pine Bancorp, Inc., Pine River, Minnesota, and Randall Bancorp, Inc., Pine River, Minnesota, and Norbanc Group, Inc., Pine River, Minnesota, to acquire 8.67 percent of the voting shares of Bankers Capital Corporation, Lusk, Wyoming, and thereby indirectly acquire Lusk State Bank, Lusk, Wyoming.

Board of Governors of the Federal Reserve System, March 15, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96-6786 Filed 3-20-96; 8:45 am]

BILLING CODE 6210-01-F

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices'' (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 4, 1996.

A. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. One Valley Bancorp of West Virginia, Inc., Charleston, West Virginia; to acquire CSB Financial Corporation, Lynchburg, Virginia, and its subsidiary, Co-operative Savings Bank, FSB, Lynchburg, Virginia, and thereby engage in operating a savings association and engage in securities and mutual funds brokerage activities, pursuant to §§ 225.25(b)(9) and (15) of the Board's Regulation Y.

B. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. Sword Financial Corporation, Horicon, Wisconsin; to engage *de novo* in making and servicing loans, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

C. Federal Reserve Bank of Kansas City (John E. Yorke, Senior Vice President) 925 Grand Avenue, Kansas City, Missouri 64198:

1. Emprise Financial Corporation, Wichita, Kansas; to acquire Wichita Federal Savings and Loan Association, Wichita, Kansas, and thereby engage in operating a savings association, pursuant to § 225.25(b)(9) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, March 15, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96-6787 Filed 3-20-96; 8:45 am]

BILLING CODE 6210-01-F

GOVERNMENT PRINTING OFFICE

Depositiory Library Council to the Public Printer; Meeting

The Depository Library Council to the Public Printer (DLC) will hold its Spring 1996 meeting on Monday, April 15, 1996, through Thursday, April 18, 1996, in Arlington, Virginia. The meeting sessions will take place from 8:30 a.m. until 5 p.m. on Monday, Tuesday, Wednesday and from 8:30 a.m. until 12 noon on Thursday. The sessions will be held at the Washington National Airport Hilton, 2399 Jefferson Davis Highway, Arlington, Virginia 22202. The purpose of this meeting is to discuss the Federal Depository Library Program. The meeting is open to the public.

A limited number of hotel rooms have been reserved at the Washington National Airport Hilton for anyone needing hotel accommodations (telephone 703–418–6800; FAX 703–418–3763). Please specify the Depository Library Council when you contact the hotel. Room cost per night is $114.

Michael F. DiMario,

Public Printer.

[FR Doc. 96–6820 Filed 3–20–96; 8:45 am]

BILLING CODE 1505–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[INFO–96–12]

Proposed Data Collections Submitted for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the

Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call the CDC Reports Clearance Officer on (404) 639–7090.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques for other forms of information technology. Send comments to Wilma Johnson, CDC Reports Clearance Officer, 1600 Clifton Road, MS–D24, Atlanta, GA 30333. Written comments should be received within 60 days of this notice.

Proposed Project

1. Vibrio Illness Investigation Report Form—(0920–0322)—Extension—The purpose of the Cholera and other *Vibrio* Illness Investigation Report Form is to collect information on illness occurring as a result of infection with *Vibrio* species. Vibrios are important pathogens in the United States, and primary septicemia, gastroenteritis, and wound infections have been associated with various species. In particular, gastroenteritis and primary septicemia have been associated with the consumption of undercooked shellfish, and particularly with raw Gulf Coast oysters. Associations have also been linked to wound infections with exposure of broken skin to seawater. Most importantly, *Vibrio cholerae* 01 is the organism responsible for cholera, a severe, dehydrating diarrheal illness. Although infections with *Vibrio cholerae* 01 are notifiable in all states, an official report form for this illness did not previously exist. The Vibrio Illness Investigation Report Form is used to record information on all *Vibrio*-related illness, as well as more detailed information on cholera illness, which is currently a reportable disease in all states. The form has a separate optional Seafood Investigation section to be completed when applicable. The form provides a consolidated, systematic method by which health departments can report such information, which is then used to gain a better understanding of the incidence, etiology, and epidemiology of all *Vibrio*-related illness occurring in the United States.

Data columns have been added to, and comments space reduced on, the form to facilitate data entry and reduce the burden. No change in the frequency of reporting has occurred or is projected.

Most respondents are epidemiologists or nurses in the local health department, but in some instances infection control nurses or physicians might complete the form. The total cost per respondent is estimated at $11.00. This is primarily salary, but also includes postage and telephone calls.

Respondents	No. of respondents	No. of responses/respondent	Avg. burden/response (in hrs.)	Total burden (in hrs.)
Local health department staff	90	1	0.33	30
Health care facility staff	45	1	0.33	15
Physicians	15	1	0.33	5
Total	.....	.....	.....	50

2. Prospective Evaluation of Health-Care Workers Exposed to Blood From Patients Infected with HIV—(0920–0131)—Extension—The HIV Infections Branch, Hospital Infections Program (HIP), Centers for Disease Control and Prevention (CDC) plans to continue surveillance of health-care workers (HCWs) exposed to the blood of persons infected with human immunodeficiency virus (HIV). This prospective evaluation, initiated in August 1983, provides essential scientific information on the risk of HIV transmission in the health care setting. The objectives of the project are to: (1) estimate the risk of HIV infection in HCWs exposed via the percutaneous, mucous-membrane, or skin route to HIV infected blood, according to type of exposure; (2) describe the type of devices and circumstances of the exposures sustained by HCWs; (3) describe the clinical natural history and development of laboratory markers of HIV infection in HCWs enrolled in this project who seroconvert to HIV; and, (4) describe the use of post-exposure chemoprophylaxis by HCWs exposed to HIV infected blood.

The design of this voluntary surveillance includes enrollment of participating institutions (respondents) throughout the United States. In the event that an HCW employed at the facility sustains an eligible exposure to HIV infected blood, the HCW is enrolled and followed prospectively. Epidemiologic data and serum for HIV antibody testing are collected within 30 days after the exposure with follow-up visits and serum samples collected at 6 weeks, 3, 6, and 12 months from the date of the exposure.

The number of respondents is the expected number of institutions participating in the project annually. The number of responses is based on the average number of forms which will be completed during each year. The 250 HCWs enrolled each year will each need four Follow-up forms completed. The number of Reports of Antiviral Prophylaxis is based on the proportion of HCWs expected to be prescribed antiviral prophylaxis (approximately 40%). The total cost to respondents is estimated at $10,525.

Respondents	No. of respondents	No. of responses/respondent	Avg. burden/response (in hrs.)	Total burden (in hrs.)
Initial Case Report Form	250	1	0.33	83
Confidential Report Form	250	1	0.25	63
Follow-up Form	250	4	0.25	250

Respondents	No. of respondents	No. of responses/respondent	Avg. burden/response (in hrs.)	Total burden (in hrs.)
Antiviral Prophylaxis Rpt	100	1	0.25	25
Total				421

Dated: March 15, 1996.

Wilma G. Johnson,

Acting Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–6792 Filed 3–20–96; 8:45 am]

BILLING CODE 4163–18–P

[30DAY–08]

Agency Forms Undergoing Paperwork Reduction Act Review

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Office on (404) 639–7090.

The following request has been submitted for review since the last publication date on February 6, 1996:

Proposed Project

Hanford Environmental Dose Reconstruction (HEDR) Project Milk Producers Survey—New—OMB approved the information collections for the ''Hanford Thyroid Disease Full Epidemiology Study'' under OMB No. 0920–0296 to determine the health effects to the public from radioactive releases from the Hanford Nuclear Site Operations during the 1940's and 1950's. A primary component of these releases was radioactive iodine. Consumption of fresh milk from cows that have eaten contaminated vegetation and fresh leafy vegetables and eggs from chickens with access to outdoor vegetation are important pathways of radioactive iodine to the human body which adversely affects the thyroid gland. To estimate the doses to the thyroid that individuals and populations could have received, historical milk cow and chicken feeding and distribution practices must be reconstructed for the downwind area. This information is particularly important for use in this ongoing study and its relation to radiation exposures. Researchers from LTG Associates will collect information from a representative sample of individuals who farmed in 7 counties within the study area during the periods of 1945 and 1951.

Respondents	No. of respondents	No. of responses/respondents	Avg. burden/response (in hrs.)
Contact Potential Sources of Names of farmers	50	1	0.16
Initial Contact of Potential Candidates	1,600	1	0.16
Scheduling Interview	400	1	0.08
Telephone Interview	400	1	2

The total annual burden is 1108. Send comments to Allison Eydt; Human Resources and Housing Branch, New Executive Office Building, Room 10235; Washington, DC 20503.

Wilma G. Johnson,

Acting Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–6793 Filed 3–20–96; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

[Docket No. 96N–0084]

Agency Emergency Processing Request Under OMB Review

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for emergency processing under the Paperwork Reduction Act of 1995. The purpose of the proposed collection of information is to enable FDA to compile lists of U.S. processors that export certain animal-derived foods to the European Community (EC). These lists must be completed by May 1, 1996, to meet EC trade requirements. To meet the EC deadline, FDA is requesting OMB approval by March 28, 1996.

DATES: Submit written comments by March 28, 1996.

ADDRESSES: Submit written comments to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: Desk Officer for FDA. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Charity B. Smith, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, rm. 16B–19, Rockville, MD 20857, 301–827–1686.

SUPPLEMENTARY INFORMATION: FDA has requested emergency processing of this proposed collection of information under section 3507(j) of the Paperwork Reduction Act of 1995 and 5 CFR 1320.13 because the information is needed to meet the May 1, 1996, EC deadline; the information is essential to the agency's mission; and public harm is reasonably likely to result if normal clearance procedures are followed.

With respect to the following collection of information, comments are invited on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility; (2) the accuracy of the agency s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information